ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ABC Abcam Plc

1,226.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Abcam Plc LSE:ABC London Ordinary Share GB00B6774699 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1,226.00 1,240.00 1,246.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Abcam Share Discussion Threads

Showing 776 to 797 of 1525 messages
Chat Pages: Latest  37  36  35  34  33  32  31  30  29  28  27  26  Older
DateSubjectAuthorDiscuss
21/1/2015
21:01
Apad

My only criticism of the abcam bod so far is that I had to get a biotech geek to translate the rns...

richscotsman
21/1/2015
20:42
hxxp://www.cambridge-news.co.uk/Abcam-announces-18-5m-buy-American-firm-Firely/story-25900575-detail/story.html
hastings
21/1/2015
19:43
Maybe you can feed some jargon back, rich :-)
I expect the share price to drift back - but bloody 'ell this is a good company.
Should I break my 10% rule!
apad

apad
21/1/2015
19:41
They give grants to scientists rich …hence enthusiasm :-)

However they get grants too:
Firefly BioWorks received a $500,000 grant from the Massachusetts Life Science Center to further develop its multiplex platform for biomarker detection. The award was made through the Center’s Small Business Matching Grant program, which is designed to provide additional support to companies that have already received Phase 2 SBIR funding from federal agencies.

Firefly says the new funds will facilitate the increase of production capacity, introduction of new products, and expansion of its team. “Our company is at an inflection point and these funds will accelerate our commercialization and the expansion of our customer base,” remarks Davide Marni, Ph.D., co-founder and CEO.

Firefly is exploiting its platform technology to develop instrument-independent assays for life sciences and clinical diagnostics. The firm’s flagship FirePlex™ assay, launched in March, is a custom 25-plex miRNA assay that can be carried out on standard cytometers.

The entire miRNA detection process can be used directly on cell lysate and tissue digest and requires just three steps; hybridize, label, and report, Firefly explains. The hybridization step binds miRNA targets to target-specific probes attached to FirePlex hydrogel particles. Labeling ligates a universal biotinylated adapter to the captured targets, and a fluorescent reporter is then bound to the universal adapter to enable miRNA detection in a flow cytometer.

One of the key features of the hydrogel particles is that they enable capture of the target molecules throughout the entire particle, not just on the surface, which Firefly claims enables expression results that are nearly independent of sample amount and generates a linear response curve below 100 attomoles of target.

apad
21/1/2015
19:04
I spoke to a stem cell scientist about firefly and she seems enthused.... Mentioned the interaction of junk dna and rna being huge potential growth sectors in research... The rest of the conversation could have been double Dutch as far as I am concerned as she went into science geek babble....

Rich

richscotsman
21/1/2015
13:57
funding constraints in educational and research establishments


May get downgrade as they say "After an initial period of modest investment, Firefly is expected to generate attractive returns in the longer term." looks like a profit downgrade with a coat on

christmasworker
21/1/2015
08:28
Strong sales imo - and now the currency is moving more in ABC's favour too.

All imo/dyor etc.

CR

cockneyrebel
21/1/2015
07:26
Hope so, my Mum wants to buy more :-)
apad

apad
21/1/2015
07:06
Can see the market disappointed with todays lukewarm news

Overall we expect total revenue growth for the period to be 13.8% on a constant currency basis and following the adverse rates of exchange seen during the period compared to H1 2013/14, growth on a reported basis to be 7.7%. Gross margin percentages at the product and geographic levels are expected to be broadly flat and in line with management's expectations, whilst the impact of the mix means that overall they are likely to be slightly less than those seen in the same period last year.

christmasworker
16/1/2015
20:31
If anything is wrong here news wise, this will shed 200p
christmasworker
16/1/2015
14:31
through resistance now richscotchman - £5 area looks the next test imo.

Bit of news for you out today:



Abcam inks partnership with IMCB to develop high-quality immunoassays for life science research

All imo/dyor etc

CR

cockneyrebel
16/1/2015
10:28
i think it will hit the upward trend line anywhere around the 466 - 462 on this mini pullback and then resume its upward movement and get the next resistance around 495 IMHO
barefoot141
14/1/2015
15:51
Broken out of an up-trend resistance line - should mean a steeper rise imo:


free stock charts from uk.advfn.com

cockneyrebel
11/1/2015
10:16
Apad... Can't blame you for finding warmer climes.... A few trees down and a couple of slates off the roof but as it is not long since the last storm anything too flimsy was already gone!

Looking forward to the trading update as ever....



Rich

richscotsman
09/1/2015
14:29
trading update 16-23rd Jan in the last 3 years.

CR

cockneyrebel
09/1/2015
10:54
The model looks as sound as a bell, rich. It always felt right - a management type couldn't set up a business to compete. Small companies in the same niche look too risky.
It seems to me that their intellectual property just gets more valuable with time - and more difficult to compete against.
I've bought 11 times since 2010 and the April purchase was bigger than the previous ten put together. This tends to be my way of working - I call the portfolio a stairway and ABC is on the top step now.
My rules prevent me buying more as it's now 7.5% of the portfolio.
This thread's a pleasure (also quite entertaining to see CR promoting the share).
Are you a rich scotsman suffering the hurricane force winds off the Hebrides, or have you moved to warmer climes? Force 12! We tend to get the fringes of those weather systems in Jersey.
apad

apad
09/1/2015
10:10
..... now I am a long term investor so not too worried about peaks and troughs.... but I really do like the look of the chart just now.... must be heading into the £5-6 zone soon.....
richscotsman
08/1/2015
20:07
Back to 130,000 products shipped over last 3 months today
trident5
08/1/2015
19:45
Apad... You beat me to it....
richscotsman
08/1/2015
18:46
www.businessweekly.co.uk/biomedtech-/18020-abcam-unlocks-opportunity-with-singapore-collaboration
apad
08/1/2015
15:28
That chart is getting better and imo.

CR

cockneyrebel
07/1/2015
11:01
A serious international broker as Nomad now - ahead of the Jan trading update.





ABCAM Plc
07 January 2015

For immediate release 7 January 2015

ABCAM PLC
("Abcam" or "the Company")
Change of Adviser
Abcam PLC (AIM: ABC), a global leader in the supply of life science research tools, is pleased to announce the appointment of J.P. Morgan Securities plc (which conducts its UK investment banking activities as J.P. Morgan Cazenove, "J.P. Morgan Cazenove") as the Company's nominated adviser and as joint corporate broker with immediate effect. Peel Hunt LLP will continue as joint corporate broker.

cockneyrebel
Chat Pages: Latest  37  36  35  34  33  32  31  30  29  28  27  26  Older

Your Recent History

Delayed Upgrade Clock